Search research articles
Contact Us
Filters
Showing results (341-350 of 369) with videos related to
Page
of 37
Sort By:
Journal for Immunotherapy of Cancer
|
July 27, 2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
Alexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, et al.
Oncotarget
|
November 16, 2017
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials
Helen J MacKay, Douglas A Levine, Victoria L Bae-Jump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2016
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Jung-Min Lee, Cody J Peer, Minshu Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2024
Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M Baptiste, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2008
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S Azad, Edwin M Posadas, Virginia E Kwitkowski, et al.
Journal of the National Cancer Institute
|
October 17, 2002
Serum proteomic patterns for detection of prostate cancer
Emanuel F Petricoin, David K Ornstein, Cloud P Paweletz, et al.
Cells
|
March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
Marina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
Molecular Cancer Therapeutics
|
November 8, 2006
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells
Philip L Lorenzi, William C Reinhold, Martina Rudelius, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Page
of 37
Search research articles
Search
Showing results (341-350 of 369) with videos related to
Sort By:
Page
of 37
Journal for Immunotherapy of Cancer
|
July 27, 2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
Alexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, et al.
Oncotarget
|
November 16, 2017
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials
Helen J MacKay, Douglas A Levine, Victoria L Bae-Jump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2016
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Jung-Min Lee, Cody J Peer, Minshu Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2024
Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M Baptiste, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2008
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S Azad, Edwin M Posadas, Virginia E Kwitkowski, et al.
Journal of the National Cancer Institute
|
October 17, 2002
Serum proteomic patterns for detection of prostate cancer
Emanuel F Petricoin, David K Ornstein, Cloud P Paweletz, et al.
Cells
|
March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
Marina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
Molecular Cancer Therapeutics
|
November 8, 2006
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells
Philip L Lorenzi, William C Reinhold, Martina Rudelius, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Page
of 37